ATE269405T1 - Tnf-alpha ribozyme und abbau-resistente mrna derivative gebunden an tnf-alpha ribozyme - Google Patents
Tnf-alpha ribozyme und abbau-resistente mrna derivative gebunden an tnf-alpha ribozymeInfo
- Publication number
- ATE269405T1 ATE269405T1 AT93924432T AT93924432T ATE269405T1 AT E269405 T1 ATE269405 T1 AT E269405T1 AT 93924432 T AT93924432 T AT 93924432T AT 93924432 T AT93924432 T AT 93924432T AT E269405 T1 ATE269405 T1 AT E269405T1
- Authority
- AT
- Austria
- Prior art keywords
- ribozymes
- alpha
- tnf
- degradation
- mrna
- Prior art date
Links
- 108020004999 messenger RNA Proteins 0.000 title abstract 5
- 102000053642 Catalytic RNA Human genes 0.000 title abstract 4
- 108090000994 Catalytic RNA Proteins 0.000 title abstract 4
- 108091092562 ribozyme Proteins 0.000 title abstract 4
- 230000000692 anti-sense effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97105892A | 1992-11-03 | 1992-11-03 | |
| PCT/AU1993/000567 WO1994010301A1 (en) | 1992-11-03 | 1993-11-03 | TNF-α RIBOZYMES AND DEGRADATION RESISTANT mRNA DERIVATIVES LINKED TO TNF-α RIBOZYMES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE269405T1 true ATE269405T1 (de) | 2004-07-15 |
Family
ID=25517882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93924432T ATE269405T1 (de) | 1992-11-03 | 1993-11-03 | Tnf-alpha ribozyme und abbau-resistente mrna derivative gebunden an tnf-alpha ribozyme |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5985620A (de) |
| EP (1) | EP0672133B1 (de) |
| JP (1) | JPH08505521A (de) |
| AT (1) | ATE269405T1 (de) |
| AU (1) | AU680843B2 (de) |
| CA (1) | CA2148368A1 (de) |
| DE (1) | DE69333550T2 (de) |
| IL (1) | IL107480A0 (de) |
| NZ (1) | NZ257484A (de) |
| WO (1) | WO1994010301A1 (de) |
| ZA (1) | ZA938208B (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0786522A2 (de) * | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatische RNA-Moleküle zur Behandlung von stenotischen Zuständen |
| US5864028A (en) * | 1992-11-03 | 1999-01-26 | Gene Shears Pty. Limited | Degradation resistant mRNA derivatives linked to TNF-α ribozymes |
| US5811300A (en) * | 1992-12-07 | 1998-09-22 | Ribozyme Pharmaceuticals, Inc. | TNF-α ribozymes |
| CA2176035A1 (en) * | 1993-11-08 | 1995-05-18 | Nassim Usman | Base-modified enzymatic nucleic acid |
| NO180167C (no) * | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
| US5700923A (en) * | 1994-09-29 | 1997-12-23 | Hybridon, Inc. | Finderons and methods of their preparation and use |
| US5650502A (en) * | 1994-11-09 | 1997-07-22 | Hybridon, Inc. | Ribozyme analogs having rigid non-nucleotidic linkers |
| US5545729A (en) * | 1994-12-22 | 1996-08-13 | Hybridon, Inc. | Stabilized ribozyme analogs |
| WO1997018312A1 (en) * | 1995-11-14 | 1997-05-22 | Vimrx Holdings, Ltd. | Chimeric oligomers having an rna-cleavage activity |
| CA2248762A1 (en) * | 1997-10-22 | 1999-04-22 | University Technologies International, Inc. | Antisense oligodeoxynucleotides regulating expression of tnf-.alpha. |
| US6228642B1 (en) | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
| US6080580A (en) * | 1998-10-05 | 2000-06-27 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression |
| US6858390B2 (en) | 1998-12-31 | 2005-02-22 | Ingeneus Corporation | Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| KR20000065690A (ko) * | 1999-04-08 | 2000-11-15 | 박종구 | 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 ｄｎａ 및 그 제조방법 |
| US7829693B2 (en) * | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| PT1237575E (pt) * | 1999-12-14 | 2008-11-17 | Genentech Inc | Antagonista de tnf-alfa e antagonista de lfa-1 para tratar a artrite reumatóide |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| EP1478730A4 (de) * | 2002-02-20 | 2006-01-25 | Sirna Therapeutics Inc | RNA-INTERFERENZ-VERMITTELTE HEMMUNG DER EXPRESSION DER GENE FÜR DIE TNF- UND TNF-REZEPTOR-SUPERFAMILIEN UNTER VERWENDUNG VON siNA (SHORT INTERFERING NUCLEIC ACID) |
| EP2986599A1 (de) | 2013-04-17 | 2016-02-24 | Pfizer Inc. | N-piperidin-3-ylbenzamid-derivate zur behandlung von herz-kreislauf-erkrankungen |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666848A (en) * | 1984-08-31 | 1987-05-19 | Cetus Corporation | Polypeptide expression using a portable temperature sensitive control cassette with a positive retroregulatory element |
| US5107065A (en) * | 1986-03-28 | 1992-04-21 | Calgene, Inc. | Anti-sense regulation of gene expression in plant cells |
| US5149635A (en) * | 1986-09-12 | 1992-09-22 | Abbott Biotech, Inc. | Messenger RNA stabilization in animal cells |
| US5254678A (en) * | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
| MC2115A1 (fr) * | 1987-12-15 | 1991-07-05 | Gene Shears Pty Ltd | Ribozynes |
| JPH05509224A (ja) * | 1990-06-19 | 1993-12-22 | コモンウェルス サイエンティフィク アンド インダストリアル リサーチ オーガナイゼイション | エンドヌクレアーゼ |
| ES2061416T3 (es) * | 1990-10-12 | 1997-03-01 | Max Planck Gesellschaft | Ribozimas modificadas. |
-
1993
- 1993-11-03 DE DE69333550T patent/DE69333550T2/de not_active Expired - Fee Related
- 1993-11-03 JP JP6510474A patent/JPH08505521A/ja active Pending
- 1993-11-03 US US08/428,252 patent/US5985620A/en not_active Expired - Fee Related
- 1993-11-03 AT AT93924432T patent/ATE269405T1/de not_active IP Right Cessation
- 1993-11-03 IL IL10748093A patent/IL107480A0/xx unknown
- 1993-11-03 AU AU54120/94A patent/AU680843B2/en not_active Ceased
- 1993-11-03 EP EP93924432A patent/EP0672133B1/de not_active Expired - Lifetime
- 1993-11-03 WO PCT/AU1993/000567 patent/WO1994010301A1/en not_active Ceased
- 1993-11-03 NZ NZ257484A patent/NZ257484A/xx not_active IP Right Cessation
- 1993-11-03 CA CA002148368A patent/CA2148368A1/en not_active Abandoned
- 1993-11-03 ZA ZA938208A patent/ZA938208B/xx unknown
-
1995
- 1995-04-04 US US08/416,516 patent/US6040159A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69333550D1 (de) | 2004-07-22 |
| JPH08505521A (ja) | 1996-06-18 |
| DE69333550T2 (de) | 2005-06-23 |
| AU5412094A (en) | 1994-05-24 |
| EP0672133A4 (de) | 1997-05-21 |
| US6040159A (en) | 2000-03-21 |
| WO1994010301A1 (en) | 1994-05-11 |
| IL107480A0 (en) | 1994-02-27 |
| CA2148368A1 (en) | 1994-05-11 |
| AU680843B2 (en) | 1997-08-14 |
| EP0672133A1 (de) | 1995-09-20 |
| US5985620A (en) | 1999-11-16 |
| NZ257484A (en) | 1997-08-22 |
| ZA938208B (en) | 1995-01-03 |
| EP0672133B1 (de) | 2004-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE269405T1 (de) | Tnf-alpha ribozyme und abbau-resistente mrna derivative gebunden an tnf-alpha ribozyme | |
| WO2002006316A3 (en) | Alpha-msh related compounds and methods of use | |
| WO2002069900A3 (en) | Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors | |
| ATE526019T1 (de) | Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen | |
| HK1044543B (zh) | 贝他分泌酶组合物及其方法 | |
| PL377553A1 (pl) | Peptydy oraz pokrewne cząsteczki modulujące aktywność czynnika wzrostu nerwów | |
| DE69533551D1 (de) | Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen | |
| DK1641483T3 (da) | Fusionsproteiner | |
| WO2004019893A3 (en) | Modulators of angiogenesis | |
| WO1997026322A3 (en) | Methods and compositions for inhibiting hexokinase | |
| Holland et al. | Proteins, exons and molecular evolution | |
| BR0009170A (pt) | ácidos nucléicos akt, polipeptìdeos e uso dos mesmos | |
| ATE287722T1 (de) | Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1 | |
| AP2000001999A0 (en) | Gene therapy method. | |
| Sawada et al. | Purification and characterization of a Trypsin‐Like serine proteinase from rat brain slices that degrades laminin and type IV collagen and stimulates protease‐activated receptor‐2 | |
| ATE226065T1 (de) | Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung | |
| EP0832213A4 (de) | TNF-alpha RIBOZYME, FNF-alpha RIBOZYMBINDENDE PROTEINE UND ABBAURESISTENTE mRNA DERIVATE, DIE MIT TNF-alpha RIBOZYMEN VERBUNDEN SIND | |
| HUP0402327A2 (hu) | Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása | |
| ATE314856T1 (de) | Ribozym-therapie zur behandlung von proliferativen augenkranheiten | |
| DE60238395D1 (de) | Ess-protein und verfahren zur verwendung davon | |
| WO2001078789A3 (en) | Poliovirus replicons encoding therapeutic agents and uses thereof | |
| ATE324906T1 (de) | Verwendung von chimäres il6-il6r in huntingtonskrankheit | |
| DE60128950D1 (de) | Proteine aus yaba monkey tumor virus mit modulatorischer aktivität | |
| ATE362531T1 (de) | Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung | |
| ATE396262T1 (de) | Rna polymerase i transkriptionsfaktor tif-ia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0672133 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |